GlassScriptPhysician profile
Phyllis Mckiernan
NPI 1194939652
$72,081.54
in general payments reported to CMS, 2019-2025
29 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,150 · 2022: $13K · 2023: $18K · 2024: $19K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $16K · Consulting Fee: $5,711 · Food and Beverage: $4,953 · Education: $89.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,492.00 |
| Travel and Lodging | $15,551.06 |
| Consulting Fee | $5,711.16 |
| Food and Beverage | $4,953.45 |
| Education | $89.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58,551.63 | 2022-2025 | |
| Incyte Corporation | $4,494.76 | 2021-2025 | Jakafi, Niktimvo |
| Pharmacosmos Therapeutics INC. | $2,717.35 | 2023-2025 | Monoferric |
| Legend Biotech USA INC. | $1,997.28 | 2024-2025 | Carvykti |
| Kadmon Pharmaceuticals LLC | $1,928.12 | 2021 | |
| Astellas Pharma US INC | $371.36 | 2022-2025 | Vyloy, Cresemba, Xospata |
| E.R. Squibb & Sons, L.L.C. | $290.96 | 2022-2025 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $226.33 | 2023-2025 | Erleada, Talvey, Rybrevant |
| Daiichi Sankyo INC. | $222.80 | 2022-2025 | Vanflyta, Enhertu |
| Merck Sharp & Dohme LLC | $161.09 | 2023-2025 | Keytruda, Prevymis, Lynparza |
| Jazz Pharmaceuticals INC. | $149.80 | 2024 | |
| Celgene Corporation | $145.80 | 2024-2025 | Breyanzi |
| Alexion Pharmaceuticals, INC. | $126.63 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $108.92 | 2021 | |
| Taiho Oncology, INC. | $86.79 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.54 | 2023-2025 | |
| Genzyme Corporation | $70.91 | 2024-2025 | |
| Geron Corporation | $52.58 | 2025 | Rytelo |
| Abbvie INC. | $46.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $46.09 | 2023-2024 | Imfinzi, Calquence |
| Eisai INC. | $43.94 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $34.28 | 2023-2024 | Libtayo |
| Immunocore Limited | $33.41 | 2024-2025 | Kimmtrak |
| Adaptive Biotechnologies Corporation | $19.86 | 2025 | Clonoseq |
| Lilly USA, LLC | $17.56 | 2025 | Verzenio, Jaypirca |
| Genmab U.S., INC. | $16.31 | 2025 | Epkinly |
| Cti Biopharma Corp. | $14.83 | 2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $14.43 | 2023 | Epkinly, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $13.89 | 2024 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Mckiernan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.